Skip to main content

Table 2 Multivariate logistic regression of relationships between remission and non-remission patients’ features

From: Evaluation of integrin αvβ3-targeted imaging for predicting disease progression in patients with high-risk differentiated thyroid cancer (using 99mTc-3PRGD2)

Variable

Remission (n = 12)

Non-remission (n = 21)

Crude OR (95% CI)

P

Adjusted OR (95% CI)

P

Age

  < 55

10

13

1

 

1

0.408

  ≥ 55

2

8

3.08 (0.53–17.80)

0.209

4.07 (0.15–113.53)

Sex

 Female

7

12

1

 

1

0.696

 Male

5

9

1.05 (0.25–4.42)

0.947

1.44 (0.23–8.89)

Pathologic type

 Papillary

11

18

1

 

1

0.473

 Follicular

1

3

1.83 (0.17–19.90)

0.618

0.26 (0.01–10.10)

Stage

 I + II

11

16

1

 

1

0.685

 III + IV

1

5

3.44 (0.35–33.61)

0.289

0.45 (0.01–20.84)

TSH-stimulated Tg

  ≤ 50

7

6

1

 

1

0.279

  > 50

5

14

3.27 (0.73–14.55)

0.120

2.87 (0.43–19.31)

99mTc-3PRGD2 uptake by metastases

 Not avid

6

2

1

 

1

0.041*

 Avid

6

19

9.50 (1.50–60.11)

0.017*

9.36 (1.10–79.83)

131I uptake by metastases

 Not avid

8

11

1

 

1

0.833

 Avid

4

10

1.82 (0.42–7.94)

0.427

0.80 (0.11–6.12)

  1. Abbreviations: OR odds ratio, CI confidence interval, Tg thyroglobulin, TSH thyroid stimulating hormone
  2. *P < 0.05